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Background: Fibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma
(MPM), warranting independent validation studies.
Methods: ELISA was used to measure cellular and secreted FBLN3 in cell lines, in plasma of xenograft tumour-bearing mice, in
plasma from two independent series of MPM and non-MPM patients and in pleural fluid from a third series. Diagnostic and
prognostic potential of FBLN3 was assessed by receiver operating characteristics curve analysis and Kaplan–Meier method,
respectively.
Results: FBLN3 was expressed in all MPM and benign mesothelial cell lines tested, and a correlation was observed between
cellular protein expression and secreted levels. Human FBLN3 was detectable in plasma of tumour-bearing mice, suggesting
that MPM cells contribute to levels of circulating FBLN3. Plasma FBLN3 was significantly elevated in MPM patients from
the Sydney cohort, but not the Vienna cohort, but the diagnostic accuracy was low (63%, (95% CI: 50.1–76.4) and 56% (95% CI:
41.5–71.0), respectively). Although FBLN3 levels in pleural effusions were not significantly different between cases and controls,
FBLN3 levels in pleural effusion fluid were found to be independently associated with prognosis (hazard ratio of 9.92 (95% CI:
2.14–45.93)).
Conclusions: These data confirm the potential prognostic value of pleural effusion FBLN3, but question the diagnostic value of
this protein in MPM patients.
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Fibulin-3 (FBLN3), encoded by the EGF-containing fibulin-like
extracellular matrix protein 1 (EFEMP1) gene, is a member of the
fibulin family of secreted extracellular glycoproteins that are
characterised by a tandem repeat of EGF-like domains and a
unique C-terminal fibulin-like module (Timpl et al, 2003; Zhang
and Marmorstein, 2010; Zhou, 2013). The fibulin family forms part
of the extracellular matrix (ECM) where they contribute to the
stabilisation of supramolecular structures such as elastic fibres and
basement membranes through interaction with various other
components of the ECM (Argraves et al, 2003; Timpl et al, 2003).
Expression of FBLN3 in condensing mesenchyme during devel-
opment, which gives rise to bone and cartilage structures, implies
an important role of this family member in skeletal development
(Zhang and Marmorstein, 2010). In adult tissue FBLN3 is widely
expressed in blood vessel walls, and in basement membranes of
epithelial and endothelial cells (Giltay et al, 1999; Timpl et al, 2003;
Zhang and Marmorstein, 2010). FBLN3 has been shown to
stimulate expression of the tissue inhibitors of matrix metallopro-
teinases (TIMP)-1 and -3 (Klenotic et al, 2004; Kim et al, 2012),
while inhibiting the expression of the matrix metalloproteinases
MMP-2, -3, -7 and -9 (Albig et al, 2006; Kim et al, 2012), thus
being directly involved in the regulation of tissue remodelling. In
addition, FBLN3 has been reported to be involved in cell growth
and tumour angiogenesis (Gallagher et al, 2005; Albig et al, 2006).
Fibulins are a relatively newly characterised group of ECM
proteins and a link between FBLN3 and cancer has only been
established over the past decade. Interestingly, the expression
pattern of FBLN3 differs between tumour types, with up- or
downregulation found depending on the cancer investigated
(Yue et al, 2007; Camaj et al, 2009; Hu et al, 2009; Sadr-Nabavi
et al, 2009; Seeliger et al, 2009; En-lin et al, 2010; Hwang et al,
2010; Nomoto et al, 2010; Wang et al, 2010; Hu et al, 2011, 2012,
2013; Kim et al, 2011; Song et al, 2011; Tong et al, 2011; Kim et al,
2012; Pass et al, 2012; Luo et al, 2013; Chen et al, 2014). FBLN3
therefore appears to have the potential to act as either tumour
suppressor or oncogene depending on the cellular context.
More recently FBLN3 has been identified as a potential
diagnostic and prognostic marker for malignant pleural mesothe-
lioma (MPM) (Pass et al, 2012). Increased abundance of the
FBLN3 protein was found in plasma and pleural effusion fluid of
MPM patients, with high levels in effusions negatively correlated
with survival. The same study also reported elevated FBLN3
expression in MPM primary tumours (Pass et al, 2012); however, a
direct link between tumour FBLN3 expression and the secreted
form of FBLN3 is yet to be made.
Towards this end, we investigated the expression and secretion
of FBLN3 in MPM and benign mesothelial cell lines in vitro and
in vivo. Our data confirm an upregulation of FBLN3 protein in
MPM cell lines, which is mirrored by an increased secretion of the
protein. In addition, we were able to confirm that levels of FBLN3
in pleural effusion may have prognostic value. However, a
diagnostic role for FBLN3 levels in plasma was not supported by
our data.
MATERIALS AND METHODS
Cell lines and protein lysis. Human MPM cell lines (H28, H226,
H2452 and MSTO) and the immortalised normal cell line MeT-5A
were obtained from the American Type Culture Collection
(Manassas, VA, USA). The additional MPM lines MM05 (Relan
et al, 2013), VMC23 (Kryeziu et al, 2013) and SPC111 (Schmitter
et al, 1992) and the normal mesothelial line LP9 (Wu et al, 1982)
were described previously. Cell lines were grown in the
corresponding medium (RPMI-1640 for all MPM lines, DMEM
for MeT-5A, M199 supplemented with 3.3 nM EGF, 400 nM
hydrocortisone and 1% insulin-transferrin-selenium for LP9)
supplemented with 10% fetal bovine serum (FBS) at 37 1C,
5% CO2 and 95% humidity. All media and supplements were
purchased from Life Technologies (Carlsbad, CA, USA) or Sigma
Aldrich (St Louis, MO, USA). All cell lines were authenticated in
September (H28, H2452, SPC111 and VMC23) or October (H226,
H2052, MSTO, MM05, MeT-5A and LP9) 2014 at the Australian
Genome Research Facility Ltd. (St Lucia, QLD, Australia) by short
tandem repeat profiling using the GenePrint 10 System (Promega,
Madison, WI, USA).
To assess secretion of FBLN3 by MPM cells in vitro, cells were
first grown to 80% confluence in T25 flasks in medium containing
FBS, then medium was replaced with 2ml serum-free medium.
Cell-conditioned medium was collected after 24 h, cell debris
removed by 5min centrifugation at 1200 r.p.m., and supernatants
stored at  80 1C. Protein lysates were prepared from the same
cells by lysis in 300 ml RIPA buffer as described previously (Linton
et al, 2014). Protein concentration was determined using the Pierce
BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions.
Mouse plasma and serum samples. Athymic (nu/nu) mice were
purchased from the Animal Resources Centre (Perth, WA,
Australia) and injected subcutaneously in the left flank with
5 106 H226 or 3 106 MSTO cells in 100 ml serum-free medium/
growth factor-reduced matrigel mix (1 : 1, matrigel from BD
Biosciences, Franklin Lakes, NJ, USA). Once tumours reached
around 300mm3, mice were killed and blood was collected via
cardiac puncture into either empty or EDTA-containing tubes.
Serum samples were allowed to clot for 60min at room
temperature before being further processed as for plasma samples
(centrifugation at 2500 r.p.m. for 20min) and both were stored at
 80 1C. Samples were collected as part of animal studies approved
by the Sydney Local Health District Animal Welfare Committee.
Patient samples. All samples were collected from patients who
had provided written informed consent and the study was
approved by the Human Research Ethics Committees at Concord
Repatriation General Hospital (CH62/6/2009/078) and Royal
Prince Alfred Hospital (X09-0322) in Sydney, the Ethical
Committee of the Medical University of Vienna (#904/2009) or
the Southern Adelaide Clinical Human Research Ethics Committee
(#381.09).
In Sydney and Vienna blood was collected by venous puncture
from (suspected) MPM patients 1 day before diagnostic procedure
(video-assisted thoracoscopic surgery/biopsy) or radical surgery
(extrapleural pneumonectomy) or from patients undergoing
cardiac or aortic surgery for severe coronary artery (CAD) or
aortic disease at participating centres. In Vienna additional control
samples were collected from lung cancer patients. Blood was
collected into 10ml K3EDTA Vacutainers (BD Biosciences) which,
within 30min of blood collection, were centrifuged for 20min at
2500 r.p.m. Plasma supernatant was stored in aliquots at  80 1C.
Pleural effusion samples were obtained from SA Pathology,
Flinders Medical Centre and Institute of Medical and Veterinary
Science SA. All pleural effusions were screened for diagnostic
suitability by accessing pathology reports, with cytological
diagnosis confirmed from subsequent radiological and/or surgical
reports. MPM samples were obtained from consecutive patients
presenting at Flinders Medical Centre between August 2011 and
June 2014, while control samples were identified from the
pathology database and collected until age and gender-matched
samples from 30 patients in each group were identified. The
median time from sample collection to confirmation of diagnosis
was 2 days. Samples were spun at 1250 r.p.m. for 10min, and the
resulting supernatant was stored immediately at  80 1C.
A summary of basic patient demographics is provided in Table 1.
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FBLN3 ELISA. FBLN3 levels were determined using the human
FBLN3 ELISA (#SEF422Hu, USCN Life Science Inc., Wuhan,
China) according to the manufacturer’s instructions at the centres
at which the respective samples were collected. Cell lysates were
diluted 1 : 2, cell-conditioned medium 1 : 4, plasma samples were
either diluted 1 : 3 (Sydney cohort and mouse plasma) or used
undiluted (Vienna cohort), and pleural effusion samples were
diluted 1 : 10 in phosphate-buffered saline. Pleural effusion samples
that showed concentrations higher than the highest standard were
diluted further and measured again. All samples were measured in
duplicate. FBLN3 levels were calculated and expressed as either
ngmg 1 total protein (cell lysates and cell-conditioned medium)
or ngml 1 (plasma and pleural effusion). Samples with readings
below those of the lowest standard were reported as 1.56 ngml 1.
Statistical analysis. FBLN3 levels are reported as mean±s.d., and
significant differences in FBLN3 levels were determined using
independent samples t-test. Receiver operating characteristics
curve analysis was used to determine the accuracy of FBLN3 to
predict correct diagnosis. Survival was calculated from date of
diagnosis until date on which analysis was performed, with patients
still alive at this time point being censored. The Kaplan–Meier log
rank method was used to assess association between FBLN3 and
survival, and if significant in univariate analysis, multivariate cox-
regression was performed to investigate the value independent
prognostic factor.
RESULTS
MPM cells express and secrete FBLN3 in vitro. FBLN3
expression was detected in all benign mesothelial (expression
range: 4.99–10.51ngmg 1) and MPM lines (expression range:
8.85–18.78ngmg 1, mean expression 13.89±3.94ngmg 1). There
was no statistically significant difference between levels in the two
groups (P¼ 0.093) (Figure 1A). Among MPM cell lines, the
average expression was higher in cells derived from tumours of
epithelioid histology (16.18±3.46 ngmg 1) than in those from
biphasic (mixed) histology (10.64±2.04 ngmg 1). Although not
reaching statistical significance (P¼ 0.066), this trend suggests a
possible correlation between histological subtype and expression of
FBLN3. Assessment of secreted FBLN3 levels in cell-conditioned
medium (Figure 1B) revealed a correlation between cellular FBLN3
expression and secretion of the protein (Spearman r¼ 0.78,
P¼ 0.017, Figure 1C), with a non-statistically significant trend
towards higher secretion observed in cells derived from epithelioid
tumours (P¼ 0.26).
FBLN3 is secreted by MPM cells in vivo. To confirm MPM cells
as the origin of circulating FBLN3, protein levels were measured in
serum and plasma collected from H226 and MSTO xenograft-
bearing mice. Although FBLN3 was not detectable in serum
samples, 3/3 plasma samples from H226-xenografts and 2/3
plasma samples from MSTO-xenografts were positive for human
FBLN3 (Figure 1D). Although from a small number of samples, the
in vivo data are consistent with the in vitro observation that MPM
cells actively secrete FBLN3, and suggest that MPM cells contribute
to the FBLN3 levels found in the blood. The lack of detection of
FBLN3 in serum samples is in line with previous findings of low
abundance of FBLN3 in serum, which may be attributed to
thrombin-mediated cleavage of FBLN3 (Pass et al, 2012).
Levels of FBLN3 in MPM patient plasma have little diagnostic
value. Abundance of FBLN3 was assessed in two independent
cohorts of MPM patients and controls. The mean levels of FBLN3
in plasma from MPM patients were 16.10±1.87 ngml 1 (Sydney)
and 11.51±1.73 ngml 1 (Vienna), and were lower than those
previously reported (Pass et al, 2012; Creaney et al, 2014; Hooper
et al, 2015). There was no significant difference in the FBLN3 levels
observed in the two cohorts (P¼ 0.077 for MPM and P¼ 0.77 for
non-MPM samples). Analysis of the Sydney cohort showed a
modest but statistically significant increase in circulating FBLN3 in
MPM patients compared with patients with pleural plaques or
CAD (16.10±1.87 vs 10.92±1.54 ngml 1, P¼ 0.039, Figure 2A),
whereas analysis of the Vienna cohort did not (11. 51±1.73 vs
11.97±3.56 ngml 1, P¼ 0.897; Figure 2B). Receiver operating
characteristics curve analyses showed an overall accuracy of 63.2%
(95% CI: 50.1–76.4%, P¼ 0.06, Figure 2C) for correct classification
as MPM for the Sydney cohort and 56.2% (95% CI: 41.5–71.0%,
P¼ 0.39, Figure 2D) for the Vienna cohort. At the lower cut-off of
29 ngml 1 (Pass et al, 2012), FBLN3 in the Sydney and Vienna
Table 1. Patient demographics
Sydney cohort Vienna cohort Pleural effusion cohort
MPM
(N¼37)
Non-MPM
(N¼32)
MPM
(N¼47)
Non-MPM
(N¼24)
MPM
(N¼30)
Non-MPM
(N¼60)
Median age (range) 71.4 (40–83) 66.3 (49–80) 64 (33–81) 66.5 (56–82) 76 (55–94) 73.5 (49–96)
Gender
Male 32 (86.5%) 27 (84.4%) 35 (74.5%) 19 (79.2%) 26 (86.7%) 51 (85%)
Female 5 (13.5%) 5 (15.6%) 12 (25.5%) 5 (20.8%) 4 (13.3%) 9 (15%)
Diagnosis
MPM 37 (100%) 47 (100%) 30 (100%)
Pleural Plaques/Pleuritis 5 (15.6%) 10 (41.7%) 30 (50%)
Adenocarcinoma
Lung 4 (16.7%) 27 (45%)
Breast 1 (1.6%)
Endometrial 1 (1.6%)
Colon 1 (1.6%)
Other lung cancer 3 (12.5%)
CAD 27 (84.4%) 7 (29.2%)
MPM histotype
Epithelioid 26 (70.3%) 35 (74.5%) 27 (90%)
Biphasic 8 (21.6%) 7 (14.9%) 2 (6.7%)
Sarcomatoid 2 (5.4%) 4 (8.5%) 1 (3.3%)
Desmoplastic 1 (2.7%) 1 (2.1%) 0
Abbreviations: CAD¼ coronary artery disease; MPM¼malignant pleural mesothelioma.
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series showed a sensitivity of 13.5% and a specificity of 96.9%, and
a sensitivity of 12.7% and a specificity of 87.5%, respectively.
Differences in circulating FBLN3 levels between patients with
different histological subtypes or associations with survival were
not observed (data not shown).
High FBLN3 levels in pleural effusion fluid are associated with
poor prognosis. Mean FBLN3 levels in MPM effusions were
628.9±853.8 ngml 1 and while comparable to those previously
published (636 ngml 1) (Pass et al, 2012; Creaney et al, 2014),
significant differences between effusions from MPM patients and
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Figure 1. MPM cell lines secrete FBLN3. Cellular (A) and secreted (B) levels of FBLN3 in MPM cell lines (grey bars¼epithelioid; black
bars¼biphasic) and benign mesothelial cells (white bars). (C) Relationship between the amount of secreted FBLN3 and cellular FBLN3 levels.
(D) FBLN3 levels in the plasma (P) or serum (S) of mice bearing human MPM xenografts of epithelioid (grey bars) or biphasic (black bars) origin. Lower
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Figure 2. FBLN3 in patient plasma. Plasma FBLN3 protein levels in the Sydney (A) and Vienna cohort (B). Mean levels in both cohorts were below
those previously reported. Mean±s.d. are represented by the lines in the scatter plots, and the cut-offs applied in the original study (Pass et al,
2012) are indicated by dotted lines. The diagnostic accuracy of plasma FBLN3 was low in both investigated cohorts: (C) Sydney cohort AUC¼ 0.63
(95% CI: 0.50–0.76); and (D) Vienna cohort AUC¼ 0.56 (95% CI: 0.41–0.71).
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patients with other conditions were not observed (Figure 3A).
Receiver operating characteristics curve analyses showed low
accuracy for correct classification of MPM patients in comparisons
with all other groups (Figure 3B). Survival analyses in the MPM
subset did not show any correlation between clinical prognostic
factors (histological subtype, age and gender), but this may be
attributed to the relatively small numbers in the various subgroups
(Table 1). Low levels of FBLN3 were, however, significantly
associated with prolonged survival, and this was independent of
whether the median for this group (Figure 3C) or the previously
published cut-off (Pass et al, 2012) (Figure 3D) was used. In
multivariate analyses including histological subtype, age and
gender as covariates, FBLN3 remained significant at both cut-offs
with hazard ratios (HRs) of 4.03 (95% CI: 1.215–13.36) and 9.92
(95% CI: 2.14–45.93), respectively.
DISCUSSION
A recent study describing elevated FBLN3 levels in MPM patients
reported that FBLN3 is overexpressed in tumour tissue, with higher
levels also present in pleural effusion fluid and plasma (Pass et al,
2012). These results suggest a possible oncogenic role for FBLN3 in
MPM. Our studies with MPM cell lines in vitro and xenografted
tumours in vivo support these previous findings in MPM tissue,
and suggest that MPM cells express and secrete FBLN3, and are a
source of FBLN3 in patient plasma samples. Interestingly, while
FBLN3 was also found to be elevated in pancreatic (Camaj et al,
2009; Seeliger et al, 2009), cervical (En-lin et al, 2010; Song et al,
2011) and brain cancer (Hu et al, 2009, 2011, 2012), in the majority
of cancer types (Yue et al, 2007; Sadr-Nabavi et al, 2009; Hwang
et al, 2010; Nomoto et al, 2010; Wang et al, 2010; Kim et al, 2011;
Tong et al, 2011; Kim et al, 2012; Luo et al, 2013; Chen et al, 2014)
the protein is downregulated. These opposing findings are further
complicated in malignant glioma where FBLN3 was found to be
upregulated compared with normal tissue, but at the same time
positively correlated with prolonged survival (Hu et al, 2009, 2011,
2012). Together these data suggest FBLN3 may have varying
context- and tissue-dependent roles. This is further highlighted by
the involvement of FBLN3 in the regulation of Akt signalling in
different types of cancer. Although epigenetic silencing of FBLN3
in nasopharyngeal carcinoma (NPC) leads to activation of the Akt
signalling pathway (Hwang et al, 2010), in pancreatic cancer
overexpression of FBLN3 also results in Akt activation (Camaj
et al, 2009). These two seemingly opposing effects are thought to be
brought about by two different mechanisms. On the one hand,
FBLN3 protein has been suggested to interfere with phosphoryla-
tion and therefore activation of Akt, meaning that low FBLN3
results in an increase in Akt signalling leading to increased
migration and invasion of NPC cells (Hwang et al, 2010). On the
other hand, in pancreatic cancer, FBLN3 was shown to indirectly
stimulate Akt phosphorylation through binding to and activating
signalling through the EGF receptor (EGFR) (Camaj et al, 2009). In
the context of MPM one can speculate that similar to the scenario
in pancreatic cancer the elevated expression of FBLN3 together
with an overexpression of EGFR (observed in 40–60% of MPM
cases (Destro et al, 2006; Edwards et al, 2006; Gaafar et al, 2010;
Rena et al, 2011)) may act in concert to lead to the increased
activation of Akt signalling frequently observed in MPM (Altomare
et al, 2005). Further investigation is needed to determine whether
FBLN3 might therefore act as an oncogene contributing to the
invasive nature of MPM.
The initial report describing FBLN3 overexpression in MPM
suggested that this can serve as a reliable diagnostic and
prognostic biomarker of the disease (Pass et al, 2012). However,
these promising findings have yet to be fully validated. The
original study reported elevated levels of cell-free FBLN3 in both
plasma and pleural effusion fluid which were able to separate,
with very high sensitivity and specificity, MPM patients from
healthy individuals and patients with effusions due to other
malignancies (Pass et al, 2012). Three validation studies (Corradi
et al, 2013; Agha et al, 2014; Creaney et al, 2014) confirmed that
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plasma levels of FBLN3 in MPM were elevated, but sensitivity and
specificity of the assay were either notably lower or cut-off levels
used to determine these were different to those originally applied,
making direct comparisons difficult. In line with these data, we
found plasma FBLN3 to be significantly elevated in one of our
two plasma series. Although overall levels of FBLN3 were much
lower than those reported in the first (Pass et al, 2012) and one
subsequent (Agha et al, 2014) report, they were more comparable
to those reported in the two other validation studies (Corradi
et al, 2013; Creaney et al, 2014). Average FBLN3 levels were lower
than the diagnostic cut-off used by Pass et al. In addition,
sensitivity and specificity of the assay were lower than those in the
original study (Pass et al, 2012) and did not reach the cut-off of
80% for both sensitivity and specificity which would classify this
protein as a good diagnostic marker according to International
Mesothelioma Interest Group guidelines (Husain et al, 2013).
Most recently, the South West Area Mesothelioma and Peme-
trexed Trial also reported on FBLN3 in plasma from MPM
patients (Hooper et al, 2015). Although this trial was not designed
to assess the diagnostic potential of any of the investigated
biomarkers, the investigators also found FBLN3 levels to be
considerably lower than reported by Pass et al (2012), with only
8% of patients having levels higher than the proposed diagnostic
cut-off of 56 ngml 1 (Hooper et al, 2015).
Creaney et al (2014) also investigated FBLN3 in pleural
effusion samples. Although the authors did not find
significant differences in FBLN3 levels between patient groups,
high FBLN3 pleural effusion levels were independently associated
with shorter survival (HR 2.05). Similarly we did not observe
significant differences between the levels of FBLN3 in the various
samples of malignant pleural effusions, but confirmed that
high effusion FBLN3 levels were independently associated with
short survival. Thus FBLN3 in pleural fluid may represent a
useful prognostic marker in MPM; however, the initial findings
supporting FBLN3 as a reliable diagnostic marker could not be
reproduced. The presence of elevated levels of FBLN3 in pleural
effusion of MPM patients together with experimental data
suggesting that FBLN3 is actively secreted by FBLN3-over-
expressing MPM tumour cells clearly asks for additional
experimental studies.
The current study has some limitations: FBLN3 assessment in
plasma and serum from xenograft-bearing mice, while limited by a
relatively small sample size, nevertheless showed that MPM
tumour cells actively secrete FBLN3 in vivo. The sample sizes of
the human material (patient cohorts) were also relatively small;
however, the results obtained in the two independent series of
plasma samples obtained at different institutions were comparable.
In addition, given its retrospective nature, the study is bound by
the inherent limitations of such studies. The use of patients
undergoing cardiac surgery as controls could also be seen as a
weakness of the study, since patients with proven asbestos
exposure would be considered the more appropriate control.
However, in particular for Australia it is known that due to the
large amounts of asbestos in the natural environment and the
heavy use of asbestos in the past resulting in large amounts also
being present in the built environment the majority of citizens have
been exposed to at least low levels of asbestos (knowingly or
unknowingly) in a non-occupational setting (LaDou et al, 2010;
Olsen et al, 2011). We therefore assume the phenomenon of (often
unknown) low level asbestos exposure also to be reflected in our
control series, and this is particularly true for the cardiac patients
in the Sydney series. Despite these limitations our data further
confirm the prognostic value of pleural effusion FBLN3, but
questions the diagnostic value of this protein in plasma of MPM
patients. The results of the present study contribute to a growing
literature on the value of FBLN3 as a biomarker in MPM, and
underline the need for prospective validation.
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